Related Experiment Video
Updated: Sep 21, 2025
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo
Rakan Radi1, Christina Huang1, Justin Elsey1
1Department of Dermatology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Abstract:
The development of targeted therapies (BRAF/MEK inhibitors) and immunotherapy have had a major impact on the treatment of melanoma. However, the majority of patients with advanced melanomas succumb to their disease. The mechanisms of resistance to both targeted therapies and immunotherapies are numerous and have been well-described. These include the alternative activation of BRAF/MEK signaling, novel compensating mutations in additional oncogenes, and loss of neoantigens. There has been limited development of small molecules that target alternative pathways in melanoma in the last two decades. We have previously identified triphenylmethanes as a class that shows activity against a wide variety of tumors. We have synthesized a novel triphenylmethane, indolium 1, and demonstrated its efficacy against an aggressive vemurafenib-resistant melanoma in vivo. Indolium 1 has a novel mechanism of action against melanoma, in that it results in induction of the tumor-suppressor EPHA3. We believe that pre-IND studies are warranted for this novel compound, given its mechanism of action and ability to inhibit the growth of vemurafenib resistant melanoma in vivo.
Insights
A novel triphenylmethane compound, indolium 1, shows efficacy against vemurafenib-resistant melanoma by inducing the tumor-suppressor EPHA3. This discovery warrants further investigation for advanced melanoma treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Advanced melanoma treatment faces challenges due to resistance to targeted therapies (BRAF/MEK inhibitors) and immunotherapies.
- Mechanisms of resistance include pathway reactivation, new mutations, and loss of neoantigens.
- Limited development of novel small molecules targeting alternative pathways in melanoma has occurred.
Purpose of the Study:
- To evaluate the efficacy of a novel triphenylmethane compound, indolium 1, against aggressive vemurafenib-resistant melanoma.
- To elucidate the mechanism of action of indolium 1 in melanoma treatment.
Main Methods:
- Synthesis of a novel triphenylmethane compound, indolium 1.
- In vivo testing of indolium 1 against vemurafenib-resistant melanoma models.
- Analysis of indolium 1's mechanism of action, focusing on tumor-suppressor EPHA3 induction.
Main Results:
- Indolium 1 demonstrated efficacy against aggressive vemurafenib-resistant melanoma in vivo.
- Indolium 1 exhibits a novel mechanism of action by inducing the tumor-suppressor EPHA3.
- The compound effectively inhibited the growth of resistant melanoma.
Conclusions:
- Indolium 1 is a promising novel compound for treating vemurafenib-resistant melanoma.
- The induction of EPHA3 represents a new therapeutic strategy for melanoma.
- Pre-Investigational New Drug (pre-IND) studies are recommended for indolium 1.
